華森製藥(002907.SZ):收到2個產品的“藥品再註冊批件”
格隆匯 8 月 5日丨華森製藥(002907.SZ)公佈,公司於近日收到重慶市藥品監督管理局(“市藥監局”)核准簽發的公司2個產品的“藥品再註冊批件”,分別為注射用甲磺酸加貝酯、酚氨咖敏片。
注射用甲磺酸加貝酯:用於急性輕型(水腫型)胰腺炎的治療,也可用於急性出血壞死型胰腺炎的輔助治療。
酚氨咖敏片:用於感冒、發熱、頭痛、神經痛及風濕痛等。
上述藥品再註冊批件的取得確保了公司上述藥品的正常生產和銷售,公司將嚴格按照要求開展相應工作,控制產品質量,持續為市場提供高品質的產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.